Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)

WuXi Bi­o­log­ics seeks spin­out, HK list­ing of bio­con­ju­gates-fo­cused joint ven­ture

An­oth­er mem­ber of the WuXi AppTec fam­i­ly is set to be spun off and sep­a­rate­ly list­ed on the Hong Kong Stock Ex­change, al­low­ing the con­tract …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.